These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An infusion reaction to cetuximab. Waxman ES Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):38-41. PubMed ID: 25391206 [No Abstract] [Full Text] [Related]
5. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. Colwell HH; Mathias SD; Ngo NH; Gitlin M; Lu ZJ; Knoop T J Infus Nurs; 2007; 30(3):153-60. PubMed ID: 17505216 [TBL] [Abstract][Full Text] [Related]
6. Management of severe infusion reactions after cetuximab. Cerman J; Melichar B; Cermanova M; Solichova D Acta Oncol; 2008; 47(8):1609-11. PubMed ID: 18607870 [No Abstract] [Full Text] [Related]
8. [Incidence of infusion reactions induced by cetuximab chemotherapy]. Maeda T; Tatematsu M; Muro K Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487 [TBL] [Abstract][Full Text] [Related]
9. Cetuximab: adverse event profile and recommendations for toxicity management. Thomas M Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844 [TBL] [Abstract][Full Text] [Related]
10. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Chung CH Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928 [TBL] [Abstract][Full Text] [Related]
17. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. Kang SP; Saif MW J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853 [No Abstract] [Full Text] [Related]
18. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. Tronconi MC; Sclafani F; Rimassa L; Carnaghi C; Personeni N; Santoro A J Clin Oncol; 2011 Aug; 29(23):e680-1. PubMed ID: 21690469 [No Abstract] [Full Text] [Related]
19. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Hollywood E Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862 [TBL] [Abstract][Full Text] [Related]
20. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration. Bryant R J Intraven Nurs; 2001; 24(3):169-73. PubMed ID: 11530362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]